SLC5A2 and diabetes mellitus: Based on these results, the 2019 European Society of Cardiology Guidelines on Diabetes and Cardiovascular Diseases listed SGLT2 inhibitors as one of the first-line glucose-lowering drugs for the treatment of T2DM patients with a high risk of cardiovascular disease (20).